Refine your search
Collections
Co-Authors
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kiran, M.
- Efficacy and Safety of a Combination of Paracetamol, Chlorpheniramine Maleate and Phenylephrine in the Symptomatic Treatment of Common Cold : Phase IV Clinical Study
Abstract Views :354 |
PDF Views:0
Authors
Affiliations
1 Medical Services, Centaur Pharmaceuticals Pvt. Ltd., IN
2 Pharmacovigilance, Centaur Pharmaceuticals Pvt. Ltd., IN
3 Dept of Pharmacology, Pad. Dr. D. Y. Patil Medical College, Navi Mumbai, IN
1 Medical Services, Centaur Pharmaceuticals Pvt. Ltd., IN
2 Pharmacovigilance, Centaur Pharmaceuticals Pvt. Ltd., IN
3 Dept of Pharmacology, Pad. Dr. D. Y. Patil Medical College, Navi Mumbai, IN
Source
The Indian Practitioner, Vol 70, No 2 (2017), Pagination: 10-15Abstract
Introduction and Background: Commoncold is one of the most frequently encountered disease in clinical practice. Though self-limiting, it accounts for major loss of work and school days so symptomatic therapy to treat the symptoms is often employed. A combination of Paracetamol, an antipyeretic/anti-inflammatory, Phenylephrine, a nasal decongestant and Chlorpheniramine maleate, an anti-histaminic is popular in the treatment of common cold. This Phase IV study evaluated the efficacy and safety of a combination of Paracetamol, Phenylephrine and Chlorpheniramine maleate in treatment of common cold. Methodology -Of 216 enrolled, 187 patients completed the study. Efficacy assessment was made by reduction in TSS and four point Likert-type scales. Safety assessment was made by analyzing the adverse events during trial. Results -Reductionin TSS from 6.58 (baseline) to 3.76 (day 3) and 1.78 (day 5). One point reduction in Likert-type symptom scale from Moderate to Mild took just 3 days. Nearly all the patients had >50% reduction in symptom score at all visit and majority of patients had complete relief from the symptom. 31 episodes of adverse events occurred and were of mild intensity. Conclusion - A combination of Paracetamol, Phenylephrine and Chlorpheniramine maleate is safe and effective in the treatment of common cold.Keywords
Paracetamol, Phenylephrine, Chlorpheniramine Maleate, Common Cold, Total Symptom Score (TSS), Likert-Type Symptom Severity Scale.References
- Mossad SB, Treatment of the common cold, BMJ 1998, 317:33–36.
- Ruth Martin Misener. Commentary on Review: a single dose of nasal decongestant reduces congestion in the short term in adults with the common cold; insufficient evidence exists on the effectiveness of repeated doses. Evidence-Based Nursing 2005; 8:12.
- Madeline Simasek e al., Treatment of the Common Cold, American Family Physician, Volume 75, Number 4, February 15, 2007.
- De Sutter et al., Antihistamines for the common cold, The Cochrane Library 2003, Issue 3.
- Knollmann, Björn C., ed. Goodman & Gilman’s the pharmacological basis of therapeutics. Vol. 12. New York: McGraw-Hill Medical, 2011.
- Mary Fran Peterlin et al. Nonprescription Chlorpheniramine Maleate and Submaximal Exercise Responses. Arch Phys Med Rehabil July 1998; 79: 827-831.
- De Sutter et al., Oral antihistamine-decongestantanalgesic combinations forthe common cold (Review), The Cochrane Library 2012, Issue 2.
- Picon et al., Symptomatic treatment of the common cold witha fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: arandomized, placebo-controlled trial BMC Infectious Diseases 2013, 13:556.
- Julia Fashner et al., Treatment of the Common Coldin Children and Adults American Family Physician, Volume 86, Number 2, July 2012.
- Eccles, R., Fietze, I. and Rose, U.-B. (2014) Rationale for Treatment of Common Cold and Flu with Multi-Ingredient Combination Products for Multi-Symptom Relief in Adults. Open Journal of Respiratory Diseases, 4, 73-82.
- DCGI Letter 4-012012-DC, CDSCO FDC Division dated 13-09-2013.
- Teneligliptin – The Newest DPP4 Inhibitor
Abstract Views :227 |
PDF Views:0
Authors
M. Kiran
1,
H. B. Chandalia
2
Affiliations
1 Medical Services, Centaur Pharmaceuticals Pvt. Ltd., IN
2 Jaslok Hospital, Mumbai, IN
1 Medical Services, Centaur Pharmaceuticals Pvt. Ltd., IN
2 Jaslok Hospital, Mumbai, IN
Source
The Indian Practitioner, Vol 70, No 2 (2017), Pagination: 21-33Abstract
Teneligliptin is the newest DPP4 inhibitor approved by the regulatory authority for the treatment of Diabetes mellitus. Teneligliptin scores over other 'gliptins' in being more economical and with better efficacy to control blood glucose and HbA1C levels. Teneligliptin additionally offers other pharmacological advantages like longer half-life, lesser IC50 value, tight and extensive binding to the DPP4 enzyme. Teneligliptin has been studies extensively for its safety and efficacy in various clinical trials conducted internationally. This review article comprehensively documents the available clinical and pharmacological data for Teneligliptin in the treatment of Diabetes mellitus.Keywords
Diabetes Mellitus, Teneligliptin, HbA1C, Fasting Blood Glucose, Post Prandial Blood Glucose.References
- Joshi SR, Parikh RM. India - diabetes capital of the world: now heading towards hypertension. J Assoc Physicians India. 2007;55:323–4.
- Kumar A, Goel MK, Jain RB, Khanna P, Chaudhary V. India towards diabetes control: Key issues. Australas Med J. 2013;6(10):524–31. [PMC free article] [PubMed] 3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes-estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(3):1047–53. [PubMed]
- Whiting Dr, Guariguata L, Weil C, Shawj. IDF Diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res ClinPract. 2011;94:311–21.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837e853.
- Lebovitz HE. Oral antidiabetic agents. In: Kahn CR, Weir GC, editors. Joslin’s diabetes mellitus. 13th ed. Philadelphia: Lea &Febiger; 1994. p. 508e529.
- DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281e303.
- Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP1) in biology and pathology. Diabetes Metab Res Rev. 2005;21:91e117.
- Edwards KL, Stapleton M, Weis J, Irons BK. An update in incretin-based therapy: A focus on glucagon-like peptide-1 receptor agonists. Diabetes TechnolTher 2012; 14: 951-967.
- Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies. J Diabetes 2012; 4: 55-67.
- Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71:1441– 1467.
- Yoshida T, Akahoshi F, Sakashita H, et al. Discovery and preclinical profile of teneligliptin(3-[(2S,4S)-4-[4-(3-methyl1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2ylcarbonyl]thiazolidine): a highly potent, selective, longlasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem. 2012;20(19):5705–5719.
- RyuichiMorishitaet. al., Teneligliptin: expectations for its pleiotropic action, Expert Opinion on Pharmacotherapy,16:3, 417-426.
- Nakamaru Y, Hayashi Y, Ikegawa R, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica. 2014;44(3):242–53.
- InvestiFarma SA. Teneglucon (teneligliptin) via oral: Argentina prescribing information. 2015. http://investi.etradeconsult.com/teneglucon/art_234/es/. Accessed 10 Aug 2015.
- Nakamaru Y, Hayashi Y, Sekine M, et al. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. ClinTher. 2014;36(5):760–9.
- Nakamaru Y, Hayashi Y, Davies M, et al. Investigation of potential pharmacokinetic interactions between teneligliptin and metformin in steady-state conditions in healthy adults. ClinTher. 2015. doi:10.1016/j.clinthera.2015.06.012.
- Kinoshita S, Kondo K. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin.
- Yoshida T, Akahoshi F, Sakashita H, et al. Discovery and preclinicalprofile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine):a highly potent, selective, longlasting and orallyactive dipeptidyl peptidase IV inhibitor for the treatment of type 2diabetes. Bioorg Med Chem. 2012;20(19):5705–19.
- Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndrome Obes.2013;6:187–95.
- Fukuda-Tsuru S, Anabuki J, Abe Y, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin improves postprandial hyperglycemia and dyslipidemia aftersingle and repeated administrations. Eur J Pharmacol.2012;696(1–3):194–202.
- Eto Et al., Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus, Diabetes, Obesity and Metabolism 14: 1040–1046, 2012.
- Kadowaki et al., Efficacy, safety and dose–response relationship ofteneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus, Diabetes, Obesity and Metabolism 15: 810–818, 2013.
- Kadowaki et al., Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: arandomized, double-blind, placebo-controlled study with anopen-label, long-term extension, Diabetes, Obesity and Metabolism 16: 418–425, 2014.
- EijiKutoha et al., Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes, J Clin Med Res. 2014;6(4):287-294.
- Rika Ito et al., Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in DrugNaive Patients with Type 2 Diabetes, Drugs R D (2015) 15:245–251.
- Takashi Kadowaki, FuyuhikoMarubayashi, Shoko Yokota, Makoto Katoh& Hiroaki Iijima (2015) Safety and efficacy of teneligliptin in Japanese patients with type2 diabetes mellitus: a pooled analysis of two Phase III clinical studies, Expert Opinion on Pharmacotherapy, 16:7, 971-981
- Bon Yun Cha, Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4inhibitor, combined with metformin in Korean patients with type2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial, Diabetes, Obesity and Metabolism 17: 309–312, 2015.
- Yoshinobu Nakamaru et al., Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-StateConditions in Healthy Adults, Clinical Therapeutics2015.
- Kadowaki T et al., Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension, Diabetes ObesMetab. 2014 May;16(5):418-25.
- Takashi Kadowaki et al., Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus, Journal of Diabetes Investigation Volume 4 Issue 6 November 2013.
- Tanaka et al., Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy, Diabetes Technology & Therapeutics, Volume 16, Number 12, 2014.
- TakehiroHashikata et al., Teneligliptin improves left ventricular diastolic functionand endothelial function in patients with diabetes, Heart Vessels 2015.
- AtefHalabi et al., Pharmacokinetics and Safety of Teneligliptin in Subjects With Hepatic Impairment, Clinical Pharmacology in Drug Development 3(4) 2014.
- AtefHalabi et al., Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment, Clinical Pharmacology in Drug Development 2(3), 2013.
- Hideo Otsuki et al., Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes, IntUrolNephrol (2014) 46:427–432.
- Wada, N., Mori, K., Nakagawa, C., Sawa, J., Kumeda, Y., Shoji, T., Emoto, M. &Inaba, M., Improved Glycemic Control with Teneligliptin in Patients with Type 2 Diabetes Mellitus on Hemodialysis: Evaluation by Continuous Glucose Monitoring, Journal of Diabetes and Its Complications, 2015.